Overview

Since 2015, we provide services in the field of Structural Biology for American and European Pharma/Biotech companies, including 2 of the largest players. We offer a full range of services in structural analysis including the Gene-to-Structure approach: • Gene preparation • Protein production • X-ray crystallography • Crystallographic Fragment Screening • Cryo-EM (Cryogenic Electron Microscopy) • Micro-ED (Microcrystal ElectronDiffraction) • Biophysical and biochemical analysis Results allows directly observe small and macro molecules in atomic details. That helps to understand protein-ligand binding or antidoby design and accelerates: • Lead selection and optimization • Structure-based drug design (SBDD) • Fragment-based drug discovery (FBDD) The success of Leaderna Biostructures derives from the highest level of expertise in science, advanced skills, and the excellent quality of services. Over the years of supporting lead optimization process in drug discovery, we have established a well-grounded position in the field of structure-based drug design (SBDD) projects. In the course of cooperation with leading pharmaceutical companies from Europe (e.g., UbiQ Bio, Selvita, Celon Pharma, OncoArendi Therapeutics, Adamed) and from the United States (IONIS Pharmaceuticals), our services have supported drug discovery efforts for such diseases as cancer, asthma, and depression. Over time of extensive collaboration with Ionis Pharmaceuticals, a world leader in RNA-targeted therapeutics, we expanded our expertise in structure determination of nucleic acid-based drugs with proteins.